• Moderna (MRNA) shares fell 9.3% premarket, extending an 18.6% two-session decline from $245.81 to $200.10, as investors questioned whether early melanoma vaccine data justify the stock's prior quadrupling.
  • The selloff reflects a valuation reset, not a trial failure: the Phase 3 INTerpath-001 study met its primary endpoint with a 42% reduction in recurrence or death, but detailed results fell short of elevated expectations.
  • An early online disclosure of the data on October 22 intensified the reaction, and the company faces a cash burn of $1.16 billion in the first half of 2026 amid a shift toward seasonal respiratory products.

A Sell-the-News Repricing

Moderna shares tumbled 9.3% in premarket trading on Monday, according to the headline quote, following a bruising two-session decline that erased 18.6% of the company's market value. The drop comes after detailed results for the company's personalized melanoma treatment, developed with Merck (MRK), appeared prematurely on an oncology website on October 22, prompting an early disclosure that caught investors off guard. Moderna closed down 17.57% at $202.63 that day and slipped another 1.25% to $200.10 on October 23, according to subsequent market reporting.

The clinical outcome was positive: in the 1,137-patient INTerpath-001 study, adding intismeran autogene to Merck's Keytruda reduced the relative hazard of recurrence or death by 42% versus Keytruda alone, with two-year recurrence-free survival at 82.2% versus 70.0%. But the magnitude of benefit, while statistically significant, did not exceed the high hopes embedded in a stock that had nearly quadrupled since the August announcement of trial success, leaving considerable anticipated commercial success priced in.

A person familiar with the matter said the early online disclosure of the data, which prompted the companies to release detailed results ahead of schedule, amplified the market reaction. "This is a classic sell-the-news event," said one analyst who spoke on condition of anonymity. "The trial didn't fail—expectations just got ahead of the science."

A Valuation Reckoning, Not a Clinical Failure

The distinction matters. The main analysis showed a 42% reduction in the hazard of recurrence or death, while a prespecified analysis of outcomes after six months showed a 58% reduction. Overall-survival results remain immature, meaning the study has not yet established that patients live longer. The companies reported no new safety signals, with severe treatment-related adverse events occurring in 14.2% of combination patients versus 13.4% with Keytruda alone.

The selloff also reflects a broader reset in investor expectations for Moderna, which is transitioning from pandemic-driven vaccine demand toward seasonal respiratory products and individualized cancer therapies. The company reported second-quarter revenue of $145 million, up slightly from $142 million a year earlier, but posted a net loss of $782 million. Cash and investments stood at $6.9 billion at June 30, down from $7.5 billion at March 31, after a $950 million litigation-settlement payment in July. First-half operating cash outflow was approximately $1.16 billion, according to the earnings release.

Management has guided to year-end cash and investments of $4.7 billion to $5.2 billion and revenue growth of up to 10% for 2026. That outlook, which is guidance rather than actual results, underscores the tension between funding a broad pipeline and a revenue base that remains far smaller than operating costs.

Merck's Smaller Sting and Wider Implications

Merck's shares fell roughly 1.7% on October 22, a much milder reaction that illustrates how the same trial can have divergent valuation consequences for two partners. For Moderna, the melanoma program is a central pillar of its post-COVID strategy; for Merck, it is one of many oncology assets.

Analyst views on the science were not uniformly negative. The main hazard ratio of 0.58 was broadly in line with, or slightly better than, expectations, according to market commentary. But Citi (C) analyst Geoff Meacham had already challenged Moderna's valuation before the decline, estimating that its pre-selloff price required approximately $13 billion in annual oncology revenue—well above Citi's own projections. Those are valuation judgments, not agreed revenue forecasts.

Intismeran is being studied in nine Phase 2/3 trials across multiple cancers, including three Phase 3 lung-cancer trials. Melanoma success does not establish efficacy in other settings. Meanwhile, the company's norovirus vaccine did not meet the statistical threshold for early success at a Phase 3 interim analysis, and the blinded study will continue with plans for an additional cohort.

Moderna's broader portfolio includes Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and newer influenza and combination products. mFLUSIVA is available for the U.S. 2026–27 flu season, while the EU-approved flu/COVID combination mCOMBRIAX is being prepared for a European launch next year. The company's July 2025 restructuring, which targeted a workforce below 5,000 by year-end and aimed to reduce annual operating expenses by $1.4 billion to $1.7 billion by 2027, remains in place but was not a new announcement tied to this week's decline.

What to Watch

The key near-term issues are interpretation of the full melanoma dataset, regulatory discussions following the results, and Moderna's cash trajectory. The company and Merck have said they are engaging regulators, but positive trial data do not constitute marketing approval. Access outside trials depends on regulatory decisions, and longer-term survival benefit is not yet established.

An approved and commercially successful personalized cancer therapy could materially diversify Moderna beyond respiratory vaccines. But the investment case still depends on regulatory approval, individualized manufacturing execution, patient uptake, reimbursement, and results in additional cancers. The present evidence supports a meaningful melanoma advance—not assured blockbuster sales or broad efficacy across cancers.

Correction: An earlier version of this article misstated the cumulative decline from Moderna's October 21 close. It was 18.6%, not 18.0%. The article has been updated to clarify that the 9.3% premarket figure is a time-specific snapshot from the headline and was not independently verified as a confirmed opening or closing price.